Oesophageal Cancer Clinical Trial
— NeoSCOPEOfficial title:
A Randomised Phase II Study of Two Pre-operative Chemoradiotherapy Regimens (Oxaliplatin and Capecitabine Followed by Radiotherapy With Either Oxaliplatin and Capecitabine or Paclitaxel and Carboplatin) for Resectable Oesophageal Cancer
About 7500 patients are diagnosed with oesophageal cancer each year in the UK of which less
than a quarter have resectable disease at diagnosis. There is a general lack of consistency
in the standard of care for patients across UK hospitals. Patients are either treated with
a) chemotherapy followed by surgical removal of the tumour, or b) chemoradiotherapy followed
by removal of the tumour by surgery, as part of their standard of care. Recent research
supports the latter treatment, as chemoradiotherapy maybe more effective at shrinking the
tumour and preventing the disease from spreading than taking chemotherapy alone. However,
there is no definitive way of identifying which treatment is best without a clinical trial.
Evidence suggests that the effect of the chemoradiotherapy currently used as standard
practice may be improved and the side effects reduced by using a different chemoradiotherapy
combination. In this trial, eligible patients will receive 2 cycles of the same chemotherapy
before being randomised to receive two different chemoradiotherapy regimens (carboplatin and
paclitaxel verses oxaliplatin and capecitabine) both of which have shown promising results
in previous studies. Patients will then have their tumour removed. The best
chemoradiotherapy regimen will then be taken forward to a Phase III trial in which
chemoradiotherapy will be compared with chemotherapy alone.
The efficacy of the regimens will be measured by counting the number of patients who i)
remain free from cancer, ii)have local or distant spread of their cancer, iii) are
successfully recruited and iv) experience toxicities. A specific set of toxicity criteria
will be used to monitor any treatment induced side-effects and provide justification for any
necessary dose modifications or withdrawal of treatment.
Status | Recruiting |
Enrollment | 85 |
Est. completion date | May 2016 |
Est. primary completion date | May 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically confirmed operable oesophageal cancer (adenocarcinoma) - Tumour must be staged as a T3, 4 or N1 (using TNM6 staging) or T3, T4a or N13 using TNM7 staging) - Maximum disease (Tumour plus nodes) length 8 cm staged with EUS and CT/PET - WHO performance status 01 - Adequate haematological, renal, respiratory, cardiac and hepatic function - The patient has provided written informed consent. Exclusion Criteria: - Histologically confirmed operable oesophageal cancer (squamous cell carcinoma) - Uncontrolled angina pectoris, myocardial infarction within 6 months, heart failure, clinically significant uncontrolled cardiac arrhythmias, or any patient with a clinically significant abnormal ECG. - Patients with any previous treatment for oesophageal carcinoma. - Siewert type 3 oesophagogastric tumours. - T4 tumours invading contiguous structures other than diaphragm, crura or mediastinal pleura. - Patients with disease in any of the following areas on the CT scan, EUS or other staging investigation: 1. Evidence of metastases in liver, lung, bone or other distant metastases. 2. Abdominal para aortic lymphadenopathy >1cm diameter on CT or >6mm diameter on EUS. 3. Invasion of tracheo-bronchial tree, aorta, pericardium or lung. - Lymphadenopathy encasing the coeliac axis (as described above, patients with single nodes lying anterior to the origin of the splenic artery and anterior to the origin of the coeliac axis are not excluded). - Any patient with a single significant medical condition which is thought likely to compromise his or her ability to tolerate any of the above therapies. - Specific contraindications to surgery, chemotherapeutic agents (including known allergies to chemotherapy) or radiotherapy. - Pregnant or lactating women and fertile women who will not be using adequate contraception during the trial. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United Kingdom | Bristol Oncology and Haematology Centre | Bristol | |
United Kingdom | Valindre NHS | Cardiff | |
United Kingdom | University Hospitals Coventry and Warwickshire | Coventry | |
United Kingdom | Royal Derby Hospital | Derby | |
United Kingdom | St James's Hospital | Leeds | |
United Kingdom | Leicester Royal Infirmary | Leicester | |
United Kingdom | St Mary's Hopsital | London | |
United Kingdom | The Christie | Manchester | |
United Kingdom | Churchill Hospital | Oxford | |
United Kingdom | Weston Park Hospital | Sheffield | |
United Kingdom | Southampton General Hospital | Southampton | |
United Kingdom | The Great Western Hospital | Swindon |
Lead Sponsor | Collaborator |
---|---|
Lisette Nixon | Cancer Research UK |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy | The efficacy of the trial treatment will be assessed by conducting analysis on the resected tumour specimen of participants undergoing surgery. This will be achieved by looking at the pathological complete response rate (pCR). | 24 months | No |
Secondary | Feasibility of recruiting 62 patients within 18 months | Feasibility of recruiting to a pre-operative chemoradiotherapy trial in the UK will be determined by recruitment within 18 months. | 18 months | No |
Secondary | Safety | The trial safety will be assessed by looking at the toxicity. Toxicities during treatment and at 6 and 12 months post-surgery will be recorded using the CTCAE version 4. SAEs will be collected in real time. The morbidity/mortality rate post surgery will also be assessed. | 3 years | Yes |
Secondary | Efficacy | The efficacy will be measured as a secondary end point by assessing the median, 3 and 5 year overall survival. | 5 years | No |
Secondary | Efficacy | The CRM (circumferential resection margin) which is a measurement of how successful the surgery was in removing all traces of tumour, will be assessed. | 24 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05685862 -
Laser Speckle Contrast Imaging, Surgical Eye & ICG Fluorescence Imaging for Perfusion Assessment of the Gastric Conduit
|
||
Recruiting |
NCT01795768 -
Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours
|
Phase 2 | |
Completed |
NCT05266300 -
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
|
||
Recruiting |
NCT03978377 -
Cardiopulmonary Toxicity of Thoracic Radiotherapy
|
||
Active, not recruiting |
NCT03653052 -
Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab
|
Phase 2 | |
Recruiting |
NCT05489250 -
The PLATON Network
|
||
Recruiting |
NCT04484636 -
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)
|
N/A | |
Terminated |
NCT01795976 -
NY-ESO-1 T Cells in OG Cancer
|
Phase 2 | |
Completed |
NCT01915693 -
ROCS (Radiotherapy After Oesophageal Cancer Stenting) Study
|
Phase 3 | |
Completed |
NCT02382237 -
Comparison of Tumor Glucose Metabolism Before and After Artificial Nutrition
|
N/A | |
Recruiting |
NCT04517448 -
Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy
|
||
Recruiting |
NCT04232735 -
Evidence Based Information Provision to Improve Decision Making After Oesophagogastric Cancer Diagnosis (SOURCE)
|
N/A | |
Recruiting |
NCT05642819 -
REVOLUTION Surgery (REVOLUTION Surgery)
|
||
Recruiting |
NCT04001478 -
Non-invasive Testing for Early oEesophageal Cancer and Dysplasia
|
||
Recruiting |
NCT02741856 -
Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05600608 -
Augmentation of Volatile Biomarkers of Oesophageal and Gastric Adenocarcinoma From the Tumour Lipidome
|
N/A | |
Recruiting |
NCT04481256 -
TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY
|
N/A | |
Recruiting |
NCT05057013 -
HMBD-001 in Advanced HER3 Positive Solid Tumours
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06046846 -
Prehabilitation Via a Mobile Application in Oesophago-gastric Cancer
|
N/A | |
Recruiting |
NCT04564482 -
PD-L1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer
|
N/A |